Erratum to: ‘Effectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial’
نویسندگان
چکیده
Erratum Unfortunately, the original version of this article [1] contained an error. There are two references in the text to the threshold for defining VAP as greater than 10^4 colony forming units/ml. These should read greater OR EQUAL to 10^4 colony forming units/ml. The error is in the abstract and in the intervention sections. In the abstract, please replace: Patients with clinically suspected VAP undergo BAL and VAP is confirmed by growth of a potential pathogen at [>]10 colony forming units per millilitre (CFU/ml). With the following correct version: Patients with clinically suspected VAP undergo BAL and VAP is confirmed by growth of a potential pathogen at [≥]10 colony forming units per millilitre (CFU/ml). In the Interventions, please replace: VAP is confirmed by the widely used threshold of growth of a potential pathogen at [>]10 colony forming units per ml (CFU/ml)(13). With the following correct version: VAP is confirmed by the widely used threshold of growth of a potential pathogen at [≥]10 colony forming units per ml (CFU/ml)(13).
منابع مشابه
Effectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial
BACKGROUND Ventilator-acquired pneumonia (VAP) is a common reason for antimicrobial therapy in the intensive care unit (ICU). Biomarker-based diagnostics could improve antimicrobial stewardship through rapid exclusion of VAP. Bronchoalveloar lavage (BAL) fluid biomarkers have previously been shown to allow the exclusion of VAP with high confidence. METHODS/DESIGN This is a prospective, multi-...
متن کاملTreatment Protocol of Ventilator-Associated Pneumonia based on Microbial Susceptibility in Pediatric Intensive Care Unit, Isfahan, Iran
Background Choosing a unique empiric treatment for ventilator associated pneumonia (VAP) can be challenging. We aimed to determine the antimicrobial susceptibility pattern of Intensive Care Unit (ICU) of the only referral pediatric hospital in Isfahan in order to design the optimal empiric treatment protocol. Materials and Methods: </strong...
متن کاملContinuous versus intermittent endotracheal cuff pressure control for the prevention of ventilator-associated respiratory infections in Vietnam: study protocol for a randomised controlled trial.
BACKGROUND Ventilator-associated respiratory infection (VARI) comprises ventilator-associated pneumonia (VAP) and ventilator-associated tracheobronchitis (VAT). Although their diagnostic criteria vary, together these are the most common hospital-acquired infections in intensive care units (ICUs) worldwide, responsible for a large proportion of antibiotic use within ICUs. Evidence-based strategi...
متن کاملStrategies for the Prevention of Ventilator-associated Pneumonia in the Intensive Care Units: A Review
Ventilator-Associated Pneumonia (VAP) accounts for 80%-90% of hospital-acquired pneumonia cases in Intensive Care Units (ICUs). VAP occurs 48-72 hours after intubation, and is observed in 27%-29% of patients with endotracheal tube, and its risk increases with the increase in the duration of mechanical ventilation. In this review study, papers published from 1996-2018 were used to investigate st...
متن کاملAntibiotic treatment of moderate-severe community-acquired pneumonia: design and rationale of a multicentre cluster-randomised cross-over trial.
BACKGROUND For the empirical treatment of community-acquired pneumonia requiring admission to a non-ICU ward, the Dutch guidelines recommend either beta-lactam monotherapy, beta-lactam and macrolide combination therapy, or fluoroquinolone monotherapy. The lack of convincing evidence to preferentially recommend any of the three empiric regimens results from intrinsic limitations of current studi...
متن کامل